- Home
- BUJA vs LEXX Comparison
BUJA vs LEXX Comparison
Compare BUJA & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUJA
- LEXX
- Stock Information
- Founded
- BUJA 2022
- LEXX 2004
- Country
- BUJA Malaysia
- LEXX Canada
- Employees
- BUJA N/A
- LEXX N/A
- Industry
- BUJA Blank Checks
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- BUJA Finance
- LEXX Health Care
- Exchange
- BUJA Nasdaq
- LEXX Nasdaq
- Market Cap
- BUJA 54.3M
- LEXX 43.5M
- IPO Year
- BUJA 2023
- LEXX N/A
- Fundamental
- Price
- BUJA $10.99
- LEXX $2.01
- Analyst Decision
- BUJA
- LEXX Strong Buy
- Analyst Count
- BUJA 0
- LEXX 2
- Target Price
- BUJA N/A
- LEXX $11.00
- AVG Volume (30 Days)
- BUJA 4.1K
- LEXX 148.5K
- Earning Date
- BUJA 01-01-0001
- LEXX 01-10-2025
- Dividend Yield
- BUJA N/A
- LEXX N/A
- EPS Growth
- BUJA N/A
- LEXX N/A
- EPS
- BUJA N/A
- LEXX N/A
- Revenue
- BUJA N/A
- LEXX $411,019.00
- Revenue This Year
- BUJA N/A
- LEXX $82.02
- Revenue Next Year
- BUJA N/A
- LEXX $95.09
- P/E Ratio
- BUJA $30.09
- LEXX N/A
- Revenue Growth
- BUJA N/A
- LEXX 34.05
- 52 Week Low
- BUJA $10.32
- LEXX $1.20
- 52 Week High
- BUJA $12.18
- LEXX $6.85
- Technical
- Relative Strength Index (RSI)
- BUJA 66.75
- LEXX 26.93
- Support Level
- BUJA $10.95
- LEXX $2.20
- Resistance Level
- BUJA $10.98
- LEXX $2.42
- Average True Range (ATR)
- BUJA 0.00
- LEXX 0.19
- MACD
- BUJA -0.00
- LEXX -0.00
- Stochastic Oscillator
- BUJA 100.00
- LEXX 7.27
About BUJA Bukit Jalil Global Acquisition 1 Ltd.
Bukit Jalil Global Acquisition 1 Ltd is a blank check company.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.